Theratechnologies (TSE:TH) had its price objective decreased by National Bank Financial from C$8.25 to C$7.00 in a research report released on Wednesday, BayStreet.CA reports. National Bank Financial currently has a sector perform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ FY2020 earnings at $0.27 EPS.
TH has been the subject of a number of other research reports. Mackie decreased their price objective on shares of Theratechnologies from C$8.15 to C$7.00 and set a hold rating for the company in a report on Friday, July 12th. Royal Bank of Canada reduced their target price on shares of Theratechnologies from C$7.00 to C$6.00 and set a sector perform rating for the company in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of C$8.75.
TSE TH opened at C$4.90 on Wednesday. Theratechnologies has a 52-week low of C$4.71 and a 52-week high of C$9.74. The company has a 50-day simple moving average of C$5.35 and a 200 day simple moving average of C$6.27. The company has a debt-to-equity ratio of 167.71, a quick ratio of 1.94 and a current ratio of 2.51. The company has a market capitalization of $387.84 million and a PE ratio of -55.06.
Theratechnologies (TSE:TH) last posted its quarterly earnings data on Thursday, July 11th. The company reported C($0.06) earnings per share (EPS) for the quarter. The company had revenue of C$20.92 million for the quarter, compared to analyst estimates of C$26.00 million. As a group, analysts forecast that Theratechnologies will post 0.07 EPS for the current fiscal year.
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Featured Story: Inflation
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.